Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label intravenous GSK3745417 in relapsed or refractory AML and high-risk MDS
NL-OMON51352Phase 1Active, not recruiting
- Sponsor
- GSK
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GSK3745417 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by GSK. Primary endpoints: Safety and tolerability, Objective response rate after induction and 1 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
GSK3745417
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON51352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51352.